Genicular Artery Embolization Shows No Benefit Over Sham for Knee Osteoarthritis

Knee osteoarthritis remains a leading cause of global disability, frequently leaving clinicians with limited options for patients who fail conservative management but are not yet candidates for total joint arthroplasty [1]. To address this gap, genicular artery embolization has emerged as a minimally invasive intervention targeting abnormal synovial neovascularization (the formation of new, pathological blood vessels) associated with chronic joint pain and inflammation [2, 3, 4]. While early observational data suggested that reducing this hypervascularity could improve patient-reported outcomes, the evidence base has been characterized by significant heterogeneity in procedural techniques and embolic materials [5, 6]. Furthermore, the lack of robust, long-term comparative data against sham procedures has made it difficult to distinguish therapeutic efficacy from the substantial placebo response often seen in osteoarthritis trials [2, 7, 8, 9]. A recent randomized controlled trial of 58 patients found that between-group differences in pain scores at 12 months were not statistically significant (7.46; 95% CI: -13.63 to 28.56; p = 0.25), suggesting that long-term symptomatic relief may be largely driven by the placebo effect [7]. These findings indicate that while the procedure is technically feasible, its clinical implementation for mild to moderate osteoarthritis requires further validation [7, 10].